Studier har vist, at insulin lispro i kombination med sulfonylurinstoffer signifikant reducerer HbA1c sammenlignet med sulfonyurinstof alene hos type 2- diabetikere på den højeste dosis af sulfonyurinstoffer.
In patients with type 2 diabetes on maximum doses of sulphonyl urea agents, studies have shown that the addition of insulin lispro significantly reduces HbA1c compared to sulphonyl urea alone.